Director Paula Soteropoulos fully exits DNTH position: 27,594 shares sold at $78.05 for $2.2M
Paula Soteropoulos, a director of Dianthus Therapeutics, sold her entire holding of 27,594 shares on 2026-03-24, liquidating to zero shares. The company reported quarterly revenue of $396,000.00 and a net loss of $-36,765,000.00 with annual revenue decline of -67.4%, indicating a development-stage biotech facing significant operational headwinds. The stock has surged +56.0% over 30 days and +97.1% over 90 days despite these fundamentals, and the sale price of $78.05 was -5.1% below the 52-week high of $86.92. A complete insider exit amid rapid share price appreciation in a cash-burning biotech with collapsing revenue warrants investor scrutiny into the company's cash runway and pipeline prospects.